Analyst Reco. Insmed Incorporated

Equities

INSM

US4576693075

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-01 EDT			5-day change	1st Jan Change
25.59 ^USD	+3.52%		+1.27%	-17.42%

04-23	Truist Starts Insmed at Buy With $48 Price Target, Sees Multi-Billion-Dollar Opportunities in Respiratory, Inflammatory Diseases	MT
04-11	Barclays Adjusts Price Target on Insmed to $40 From $37, Maintains Overweight Rating	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Truist Starts Insmed at Buy With $48 Price Target, Sees Multi-Billion-Dollar Opportunities in Respiratory, Inflammatory Diseases	04-23	MT
Barclays Adjusts Price Target on Insmed to $40 From $37, Maintains Overweight Rating	04-11	MT
UBS Initiates Coverage on Insmed With Buy Rating, $46 Price Target	02-27	MT
Wolfe Research Starts Insmed With Outperform Rating, $42 Price Target	02-15	MT
Mizuho Raises Price Target on Insmed to $35 From $33, Maintains Buy Rating	23-10-27	MT
Cantor Fitzgerald Increases Price Target on Insmed to $54 From $46, Maintains Overweight Rating	23-09-21	MT
Evercore ISI Adjusts Price Target on Insmed to $42 From $32, Maintains Outperform Rating	23-09-07	MT
Mizuho Securities Ups Price Target on Insmed to $33 From $30, Maintains Buy Rating	23-09-06	MT
Guggenheim Initiates Insmed With Buy Rating, $50 Price Target	23-07-26	MT
Mizuho Securities Ups Price Target on Insmed to $30 From $28, Maintains Buy Rating	23-07-26	MT
Cantor Fitzgerald Adjusts Price Target on Insmed to $46 From $49, Maintains Overweight Rating	23-02-24	MT
Barclays Adjusts Insmed Price Target to $35 From $37, Maintains Overweight Rating	23-01-20	MT
Goldman Sachs Cuts Price Target on Insmed to $39 From $44, Keeps Buy Rating	23-01-09	MT
Mizuho Initiates Insmed With Buy Rating, Sets Price Target at $28	22-12-09	MT
Barclays Starts Insmed at Overweight With $37 Price Target	22-12-07	MT
BofA Securities Starts Insmed at Buy With $39 Price Target	22-11-18	MT
Cantor Fitzgerald Adjusts Price Target on Insmed to $49 From $53, Reiterates Overweight Rating	22-10-25	MT
Cowen Adjusts Insmed's Price Target to $53 From $56, Maintains Outperform Rating	22-10-21	MT
Morgan Stanley Adjusts Price Target for Insmed to $41 From $46, Maintains Overweight Rating	22-07-14	MT
Berenberg Bank Terminates Coverage of 85 Companies in Consumer Discretionary, Healthcare, Industrial Tech, REIT, Software and IT Services Sectors	22-07-01	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Insmed Incorporated

Equities

INSM

US4576693075

Analyst Reco.

Filters